Vertex's JOURNAVX Shows High Opioid-Free Recovery Rates in Plastic Surgery Study
Event summary
- Vertex's Phase 4 study of JOURNAVX (suzetrigine) showed 90.9% of patients were opioid-free post-surgery, significantly higher than standard multimodal treatments.
- The study involved 99 patients undergoing aesthetic and reconstructive surgeries, with 90.7% rating JOURNAVX's effectiveness as excellent, very good, or good.
- JOURNAVX was generally safe with no serious adverse events related to the drug, and adverse events were mild or moderate in severity.
- Data will be presented at the AAPM PainConnect 2026 meeting on March 6, 2026.
The big picture
Vertex's JOURNAVX represents a strategic shift in pain management, particularly in the context of the opioid crisis. The study's results highlight the potential for non-opioid alternatives in surgical settings, aligning with broader industry trends toward reducing opioid dependence. Vertex's ability to position JOURNAVX as a core element of opioid-free multimodal treatment could significantly impact its market share in the acute pain management space.
What we're watching
- Market Adoption
- How quickly JOURNAVX can gain traction among surgeons and patients as an alternative to opioids in plastic surgery.
- Regulatory Expansion
- Whether Vertex can leverage these results to expand JOURNAVX's approval to additional surgical indications.
- Competitive Positioning
- The pace at which Vertex can differentiate JOURNAVX from other non-opioid pain management options in the market.
Related topics